DTP Branches and Offices
MDA-MB-435, and its derivation MDA-N, are Melanoma cell lines, not breast cancer cell lines.
MDA-MB-435, a member of the NCI-DTP panel of 60 human tumor cell lines, has been used for decades as a model of metastatic human breast cancer. This cell line was derived at M.D. Anderson in 1976 from a pleural effusion from a 31-year old woman with a history of breast cancer (Cailleau R, Olive M, Cruciger QV. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro. 1978 Nov;14(11):911-5.; Brinkley BR, Beall PT, Wible LJ, Mace ML, Turner DS, Cailleau RM. Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro. Cancer Res. 1980 Sep;40(9):3118-29.) Further background information on this cell line may be found at the M.D. Anderson Breast Cancer Cell Line Database.
Recent advances in gene expression analysis allow the opportunity to more fully characterize tumor cell lines. Analysis of MDA-MB-435, in conjunction with the rest of the NCI60 panel, revealed that the pattern of gene expression for MDA-MB-435 more closely resembled that of melanoma cell lines than of other breast tumor lines (Ross et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000 Mar;24(3):227-3.)
These findings prompted Ellison et al. to undertake a more detailed study of the characteristics of MDA-MB-435 (Ellison G, Klinowska T, Westwood RF, Docter E, French T, Fox JC. Further evidence to support the melanocytic origin of MDA-MB-435. Mol Pathol. 2002 Oct;55(5):294-9.). They measured expression of several breast-specific genes and several melanoma-specific genes in MDA-MB-435 (obtained from the American Type Culture Collection), as well as in other breast tumor cell lines, melanoma cell lines and normal breast. Breast-specific genes were not detectably expressed in MDA-MB-435 or in the melanoma lines, but were detected in most of the breast tumor cell lines as well as normal breast. However, melanocyte-specific genes were expressed in MDA-MB-435, as well as in most of the melanoma lines, but were not detectable in the other breast tumor cell lines. Additionally, xenografts of MDA-MB-435 implanted into mammary fat pads of female SCID mice showed immunohistochemical staining consistent with melanocytic origin.
More recently single nucleotide polymorphism (SNP) array analysis revealed that MDA-MB-435 is derived from the same individual as the melanoma cell line M14 (Garraway LA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005 Jul 7;436(7047):117-22.; http://www.sanger.ac.uk/genetics/CGP/NCI60/).
The NCI Developmental Therapeutics Program obtained MDA-MB-435 from Dr. Patricia Steeg (NCI) — Dr. Steeg obtained the line from M.D. Anderson. The DTP has obtained DNA fingerprinting analysis of the MDA-MB-435 in the DTP repository, as well as MDA-MB-435 from the ATCC (which obtained their sample from M.D. Anderson). DNA fingerprinting on all MDA-MB-435 samples are consistent with their derivation from the same individual. Thus the mix-up with the melanoma cell line M14 likely happened early in the history of the cell line.
Note added 8/5/2009: The panel designation for this cell line continues to be a topic for discussion, as seen in a recent publication by Chambers. (MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res. 2009 Jul 1;69(13):5292-3.)
Note added 8/2007: A recent publication by Rae et al. used karyotype, CGH, and microsatalite polymorphism analyses, combined with bioinformatics analysis of gene expression and SNP data and concluded that “All currently available stocks of MDA-MB-435 cells are derived from the M14 melanoma cell line.” (Rae JM et al. MDA-MB-435 cells are derived from M14 Melanoma cells — a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat. 2007 Jul;104(1):13-9.)
Note added 8/2011: Identifiler DNA profiling confirms that MDA-N is derived from MDA-MB-435, and we therefore consider MDA-N to be a melanoma cell line.
NCI-60 Human Tumor Cell Lines Screen
- Main
- Announcement: Update to NCI-60 (August 2023)
- Compound Submission
- Data Retrieval and Testing Decisions
- List of NCI-60 Human Tumor Cell Lines
- Screening methodology (One-dose and Five-dose Assay)
- Sample Handling and Preparation
- Database of Screening Results
- Molecular Characterization of NCI-60
- Publications